183 related articles for article (PubMed ID: 38360867)
1. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
2. A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis.
Vanni F; Lopresti L; Zurli V; Kabanova A; Cattaneo F; Sicuranza A; Gozzetti A; Gemma S; Zisterer DM; Bocchia M; Campiani G; Baldari CT; Butini S; Ulivieri C
Pharmacol Res; 2021 Dec; 174():105965. PubMed ID: 34732370
[TBL] [Abstract][Full Text] [Related]
3. p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formation.
Lopresti L; Capitani N; Tatangelo V; Tangredi C; Boncompagni G; Frezzato F; Visentin A; Marotta G; Ciofini S; Gozzetti A; Bocchia M; Trentin L; Baldari CT; Patrussi L
Front Cell Dev Biol; 2024; 12():1297116. PubMed ID: 38389706
[No Abstract] [Full Text] [Related]
4. Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment.
Patrussi L; Manganaro N; Capitani N; Ulivieri C; Tatangelo V; Libonati F; Finetti F; Frezzato F; Visentin A; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Blood; 2021 Apr; 137(16):2182-2195. PubMed ID: 33181836
[TBL] [Abstract][Full Text] [Related]
5. p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
Patrussi L; Capitani N; Ulivieri C; Manganaro N; Granai M; Cattaneo F; Kabanova A; Mundo L; Gobessi S; Frezzato F; Visentin A; Finetti F; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Leoncini L; Efremov DG; Baldari CT
Haematologica; 2019 Oct; 104(10):2040-2052. PubMed ID: 30819907
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
[TBL] [Abstract][Full Text] [Related]
7. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4
Roessner PM; Llaó Cid L; Lupar E; Roider T; Bordas M; Schifflers C; Arseni L; Gaupel AC; Kilpert F; Krötschel M; Arnold SJ; Sellner L; Colomer D; Stilgenbauer S; Dietrich S; Lichter P; Izcue A; Seiffert M
Leukemia; 2021 Aug; 35(8):2311-2324. PubMed ID: 33526861
[TBL] [Abstract][Full Text] [Related]
8. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
Alhakeem SS; McKenna MK; Oben KZ; Noothi SK; Rivas JR; Hildebrandt GC; Fleischman RA; Rangnekar VM; Muthusamy N; Bondada S
J Immunol; 2018 Jun; 200(12):4180-4189. PubMed ID: 29712773
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
11. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia.
Pagano G; Botana IF; Wierz M; Roessner PM; Ioannou N; Zhou X; Al-Hity G; Borne C; Gargiulo E; Gonder S; Qu B; Stamatopoulos B; Ramsay AG; Seiffert M; Largeot A; Moussay E; Paggetti J
Haematologica; 2023 Nov; 108(11):3011-3024. PubMed ID: 37345470
[TBL] [Abstract][Full Text] [Related]
14. SLAMF6 as a Regulator of Exhausted CD8
Yigit B; Wang N; Ten Hacken E; Chen SS; Bhan AK; Suarez-Fueyo A; Katsuyama E; Tsokos GC; Chiorazzi N; Wu CJ; Burger JA; Herzog RW; Engel P; Terhorst C
Cancer Immunol Res; 2019 Sep; 7(9):1485-1496. PubMed ID: 31315913
[TBL] [Abstract][Full Text] [Related]
15. Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Cattaneo F; Patrussi L; Capitani N; Frezzato F; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncotarget; 2016 Aug; 7(35):57086-57098. PubMed ID: 27494881
[TBL] [Abstract][Full Text] [Related]
16. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
[TBL] [Abstract][Full Text] [Related]
17. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia.
Smith AL; Skupa SA; Eiken AP; Reznicek TE; Schmitz E; Williams N; Moore DY; D'Angelo CR; Kallam A; Lunning MA; Bociek RG; Vose JM; Mohamed E; Mahr AR; Denton PW; Powell B; Bollag G; Rowley MJ; El-Gamal D
JCI Insight; 2024 May; 9(10):. PubMed ID: 38775157
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion.
Francia di Celle P; Mariani S; Riera L; Stacchini A; Reato G; Foa R
Blood; 1996 May; 87(10):4382-9. PubMed ID: 8639799
[TBL] [Abstract][Full Text] [Related]
20. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
